<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638117</url>
  </required_header>
  <id_info>
    <org_study_id>AP-TRPV1_PI-02</org_study_id>
    <nct_id>NCT01638117</nct_id>
  </id_info>
  <brief_title>Cumulative Irritation Test of PAC-14028 in Healthy Volunteers</brief_title>
  <official_title>Phase I Clinical Trial to Investigate the Cumulative Skin Irritation of PAC-14028 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amorepacific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amorepacific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the cumulative irritation potential of the products&#xD;
      listed by the Sponsor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy, adult volunteers of either sex will be patched daily on his/her arm with multiple&#xD;
      strengths of PAC-14028 cream, non-active comparator and an active comparator over the course&#xD;
      of 21 consecutive days. Twenty-four hours after each application, the Finn-chamber patches&#xD;
      will be removed and the site evaluated using a five-point scale for irritation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Irritation Score (5-point scale, 0-4)</measure>
    <time_frame>Daily for 21 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PAC14028-Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PAC-14028 Cream Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC14028-0.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 Cream 0.1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC14028-0.3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 Cream 0.3%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC14028-1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 Cream 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Lauryl Sulfate, 0.5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PAC14028-Vehicle</intervention_name>
    <description>PAC-14028 Cream Vehicle, Daily for up to 21 days</description>
    <arm_group_label>PAC14028-Vehicle</arm_group_label>
    <other_name>PAC-14208 cream vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC14028-0.1</intervention_name>
    <description>PAC-14028 Cream, 0.1%, Daily for up to 21 days</description>
    <arm_group_label>PAC14028-0.1</arm_group_label>
    <other_name>PAC-14208 Cream 0.1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC14028-0.3</intervention_name>
    <description>PAC-14028 Cream, 0.3%, Daily for up to 21 days</description>
    <arm_group_label>PAC14028-0.3</arm_group_label>
    <other_name>PAC-14208 Cream 0.3%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC14028-1.0</intervention_name>
    <description>PAC-14028 Cream, 1%, Daily for up to 21 days</description>
    <arm_group_label>PAC14028-1.0</arm_group_label>
    <other_name>PAC-14028 Cream 1.0%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline, Daily for up to 21 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% Sodium chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Positive</intervention_name>
    <description>Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days</description>
    <arm_group_label>Positive control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers of either sex, at least 20 years to 59 Years.&#xD;
&#xD;
          -  Females must be of non-childbearing potential (i.e., post-menopausal or surgically&#xD;
             sterile). All females must submit to a urine pregnancy test and have a negative result&#xD;
             at Day 1 and at the final study visit.&#xD;
&#xD;
          -  Subjects may be of any skin type or race providing their degree of skin pigmentation&#xD;
             does not interfere with readings of skin reactions.&#xD;
&#xD;
          -  Who voluntarily decides study participation after receiving detailed explanation about&#xD;
             the study and fully understanding it and who provides written consent for compliance&#xD;
             with study requirement including proper contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atopic dermatitis/eczema, psoriasis will be excluded. Any skin disease that would in&#xD;
             any way confound interpretation of the study results.&#xD;
&#xD;
          -  Asthma and chronic bronchitis will be excluded.&#xD;
&#xD;
          -  Inability to evaluate the skin in and around the potential patch test sites on the arm&#xD;
             due to erythema, eschar, excoriation, tattoos, scars, unevenness in skin tones, or&#xD;
             other skin damage or abnormality.&#xD;
&#xD;
          -  A history of sensitivity to any component of any of the formulations and the Finn&#xD;
             chamber.&#xD;
&#xD;
          -  Used systemic or topical corticosteroids or other immunosuppressive medications within&#xD;
             1 weeks of the Day 1 visit.&#xD;
&#xD;
          -  Used nonsteroidal anti-inflammatory medications within 2 weeks of the Day 1 visit.&#xD;
&#xD;
          -  Received immunizations within 2 weeks of the Day 1 visit.&#xD;
&#xD;
          -  Any major illness within 4 weeks of the Day 1 visit.&#xD;
&#xD;
          -  Female who is pregnant, trying to become pregnant, or breast feeding&#xD;
&#xD;
          -  Use of chronic medications (such as antihistamines, corticosteroids, analgesics and&#xD;
             anti-inflammatories) for one week before and during the study.&#xD;
&#xD;
          -  Currently using any medication that, in the opinion of the investigator, may affect&#xD;
             the evaluation of the study product or place the subject at undue risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu-Han Kim, M.D.,Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital, Department of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital, Department of Dermatology</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>January 19, 2014</last_update_submitted>
  <last_update_submitted_qc>January 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

